Plexxikon CEO: Expect Business As Usual, After Whopping $805 Million Daiichi Buyout
A bidding war for a start-up developing a promising late-stage melanoma drug drives the deal value sky high.
A bidding war for a start-up developing a promising late-stage melanoma drug drives the deal value sky high.